PHASE-II EVALUATION OF MITOXANTRONE PLUS CISPLATINUM IN PATIENTS WITHADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

Authors
ATIBA JO GREEN SJ HYNES HE OSBORNE CK MILLER TP DAVIDNER M
Citation
Jo. Atiba et al., PHASE-II EVALUATION OF MITOXANTRONE PLUS CISPLATINUM IN PATIENTS WITHADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Investigational new drugs, 12(2), 1994, pp. 129-132
Citations number
9
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
12
Issue
2
Year of publication
1994
Pages
129 - 132
Database
ISI
SICI code
0167-6997(1994)12:2<129:PEOMPC>2.0.ZU;2-H
Abstract
The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m(2) to 12.0 mg/m(2)) and cis-platinum (10 0 mg/m(2)) in 30 patients with advanced breast cancer as second-line t herapy. There were 2 partial responses in 29 eligible patients. Toxici ty was considerable, with 27 patients having grade 3 or 4 toxicity. Gr ade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia , leukopenia and anemia. The combination of mitoxantrone plus cis-plat inum has minimal activity as second-line therapy in metastatic breast cancer.